sickle cell disease

International trial introduces another curative option for sickle cell disease 

The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.

(iStock image)

VUMC hosts symposium on stem cell transplants and cellular therapies

The Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium offers clinicians detailed information on the latest developments for hematological diseases, ranging from immunotherapies for blood cancers to new, curative therapies for sickle cell disease.

Michael DeBaun, MD, MS, MPH

VUMC’s DeBaun elected president-elect of the American Pediatric Society

Vanderbilt’s Michael DeBaun, MD, MS, MPH, has been elected president-elect of the American Pediatric Society.

No detail is too small and no task too big for research administrative officer Mustafa Nateqi

Nateqi’s can-do attitude and dedication earn him a Credo Award.

DeBaun’s mentoring honored by American Society of Hematology

Michael DeBaun, MD, MPH, has been awarded the American Society of Hematology’s 2019 ASH Mentor Award for his sustained and outstanding commitment to the training and career development of early career hematologists.

young african american man in hospital

Risk of death in sickle cell disease

Two factors commonly used to evaluate patients with sickle cell disease are associated with each other and can predict increased mortality, Vanderbilt researchers have discovered.

1 2